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Microbiota gastrointestinal y síndrome de
intestino irritable. Respuesta a
García-Mazcorro
Mr. Editor:
We thank García-Mazcorro et al.1 for their interest and com-
ments on our review.2 In relation to their ﬁrst point, we
completely agree with them concerning the term intestinal
«ﬂora». Microbiota is the correct word, deﬁned as the com-
munity of living microorganisms residing in a determined
ecological niche, and we use it, not only in the title, but
throughout the article (79 times to be exact), whereas the
less precise but commonly used ﬂora is employed only 5
times.2
Secondly, the 16S ribosomal RNA (rRNA) gene is one of
the components of the small subunit (30S) of the ribosome
and is present in all bacteria and archaea. It is the genetic
marker used in bacterial phylogenetic analysis and is widely
used in an endless number of studies. This gene sequence
is approximately 1,550 bp long and is composed of 9 highly
variable regions or hypervariable regions ﬂanked by constant
regions. The differences in sequencing of these hypervari-
able regions make it possible to taxonomically identify the
bacteria present in study samples (for example, in stools
and intestinal mucosa).3 The «rrs» gene, also known as 16S
ribosomal DNA or 16S rDNA, as mentioned in table 3 of our
on this marker. Illumina belongs to the «next generation»
sequencing technologies that are limited by the length of
the sequences they can provide, and so speciﬁc regions of
the 16S rRNA gene must be selected in the analysis.3 Other
sequencing strategies and equipment currently exist that
were designed for completion and correction.
Thirdly, the inability to absolutely establish the micro-
biota that is characteristic of IBS due to the factors
mentioned by García-Mazcorro et al. is a fundamental aspect
of our review.2 In fact, that was why we reached the conclu-
sion that even though there is evidence that the intestinal
microbiota is different in persons with IBS from that of
normal subjects (level 3b evidence, grade B recommenda-
tion), it is not possible to establish a microbial composition
that is speciﬁc for this disorder (level 3b evidence, grade B
recommendation).2
On the other hand, we agree that the taxonomic lev-
els found were not mentioned in some cases, but some of
the studies reviewed only reported the differences in micro-
bial groups. And ﬁnally, we agree that our already extensive
review fell short of analyzing the use of probiotics, prebi-
otics, and even synbiotics, in the treatment of IBS, but we
felt these topics should be the subject of another review.
As a matter of fact, a very recent systematic review of
the literature has reported that probiotics were superior
to placebo due to a lower frequency of IBS symptom per-
sistence (55.8% vs. 73.1%).4 In addition, probiotics were
shown to be superior to placebo in the improvement of
overall symptoms, abdominal pain, subjective abdominal
bloating, and ﬂatulence. Speciﬁcally, it was Biﬁdobacterium
spp that showed a tendency toward the improvement of
overall symptoms and abdominal pain, but determiningarticle, encodes 16S rRNA. Even though there are limita-
tions in sequencing based on 16S rRNA, it continues to be
the gold standard due to the extensive databases based
DOI of original article:http://dx.doi.org/10.1016/j.rgmxen.
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stablished. The authors also found that there were very
ew studies on prebiotics and synbiotics.4 Another review
ound that B. infantis 35624 was effective in improving sub-
ective bloating in IBS in general and B. animalis DN-173
10 in patients with constipation predominant IBS (IBS-C).5
urthermore, the relation between diet and the micro-
iota should also be analyzed. For example, low FODMAP
Fermentable Oligosaccharides Disaccharides, Monosaccha-
ides, And Polyols) diets that improve IBS symptoms also
ppear to reduce the concentration and proportion of biﬁ-
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obacteria in stools determined through ﬂuorescence in situ
ybridization.6
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